Interestingly, 15/187 glioma patients (2 GBMs, 13 LGGs) in our cohort harbored TP53:IDH1 co-mutations (Supplementary Fig. 4A, B), and had better survival than patients have TP53 single mutant (Supplementary Fig. 4C). Here, IDH1 is linked to central nervous system cancer.